Detalhe da pesquisa
1.
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
Paediatr Drugs
; 26(4): 411-427, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649595